跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PANCREASE MT 20 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PANCREASE MT 20
Authorized
STANDARD
PANCREASE MT 20
vivus llc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
42996af93d0610a2
Company
vivus llc.
Type
Standard
Approval Details
Approval Id
42996af93d0610a2
Drug Approval Canada Name
PANCREASE MT 20
Product Name
PANCREASE MT 20
Status
Marketed
Status Date
2020-12-21
Original Market Date
2020-12-21
Din
02503441
Drug Class
Human
Dosage Form
Capsule (Delayed Release)
Route Of Administration
Oral
Schedule
Prescription , Schedule D
Ahfs
56:16.00
Atc Original
A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC)
Atc Name
a 09 aa 02
Aig Number
0302964047
Company Name
vivus llc.
Company Address
900 East Hamilton Avenue, Suite 550, Campbell, California, United States, 95008
Active Ingredients
AMYLASE
61000 UNIT
LIPASE
21000 UNIT
PROTEASE
37000 UNIT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
42996af93d0610a2
Type
Standard
Back to Health Canada Approvals